During the 12th Annual Scientific Sessions (January 29 to February 1, 2009) of the Society for Cardiovascular Magnetic Resonance (SCMR), the world's major international society for cardiovascular imaging, the role of magnetic resonance imaging to assess the effect of therapy in patients with acute myocardial infarction will be demonstrated in a series of papers. Cardiovascular magnetic resonance imaging offers the ability to measure after therapy the size a myocardial infarction would have had if no therapy had been performed (Salvage-imaging). This allows physicians to assess the effect of their intervention and thus, to perform studies to optimize the benefit to their patients.
Before this new technique became available, this knowledge could only be generated to compare large groups of patients who underwent different treatment regimes to average the differences between the groups. With the new technique, these differences can now be corrected for and thus much faster progress towards individually optimized therapy can be
generated.
"Using the new magnetic resonance technique we have been able to show in a relatively small trial of 220 patients, that therapy in patients after myocardial infarction can be optimized adding antioxidative agents to standard therapy," said Holger Thiele, MD, from the University of Leipzig, Germany. "We had known this from animal data before and were now
able to demonstrate this effect in patients using magnetic resonance imaging as an endpoint."
Magnetic resonance imaging has already been established as an endpoint for cardiac function, size and measuring the size of irreversible myocardial damage after myocardial infarction. It is now expanding to a further endpoint for myocardial salvage in patients with acute myocardial infarction.
About the Society for Cardiovascular Magnetic Resonance (SCMR)
Founded in 1994, SCMR is a professional association whose vision is to be the recognized representative and advocate for physicians, scientists and technologists who work in the field of cardiovascular magnetic resonance. SCMR endeavors to be the principal international, independent organization committed to the further development of cardiovascular magnetic resonance through education, quality control, research, and training. For more information, visit www.scmr.org.
Business & Industry
- U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
- AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
- European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options
- AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease
- Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
Research & Development
- Researchers publish final results of key clinical trial for gene therapy for sickle cell disease
- Optimal timing maximises Paxlovid benefits for treating COVID-19
- Researchers develop a new way to safely boost immune cells to fight cancer
- How the Birmingham Drug Discovery Hub created an investment-ready 'drug library'
- Common HIV treatments may aid Alzheimer's disease patients
- Next-generation treatments hitch a ride into cancer cells
- Groundbreaking treatment approach shows promise in hard-to-treat cancers
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
- FDA approves first gene therapies to treat patients with sickle cell disease
- FDA approves first therapy for rare type of non-cancerous tumors
- First electronic product information (ePI) published for selected human medicines
- FDA approves first treatment for patients with rare inherited blood clotting disorder